Background: Older adults with acute myeloid leukemia (AML) represent a vulnerable
population in whom disease-based and clinical risk factors, patient goals, prognosis, and …

The choice of treatment approach and outcome in acute myeloid leukemia (AML) depends
on the age of the patient. In younger patients, arbitrarily defined as being younger than 60 …

Purpose CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin
that delivers a synergistic 5: 1 drug ratio into leukemia cells to a greater extent than normal …

Many tumor cells become resistant to commonly used cytotoxic drugs due to the
overexpression of ATP-binding cassette (ABC) transporters, namely P-glycoprotein (P-gp) …

Background A complete remission is essential for prolonging survival in patients with acute
myeloid leukemia (AML). Daunorubicin is a cornerstone of the induction regimen, but the …

One of the major causes of failure in cancer chemotherapy is multidrug resistance (MDR),
where cancer cells simultaneously become resistant to different anticancer drugs. Over …

Purpose The prognosis of elderly patients with acute myeloid leukemia (AML) is still dismal
even with intensive chemotherapy. In this trial, we compared the antileukemic activity of …

Abstract Pevonedistat (TAK-924/MLN4924) is a novel inhibitor of NEDD8-activating enzyme
(NAE) with single-agent activity in relapsed/refractory acute myeloid leukemia (AML). We …

Mounting evidence indicates that the presence of measurable (“minimal”) residual disease
(MRD), defined as posttherapy persistence of leukemic cells at levels below morphologic …

This trial was conducted to determine the dose‐limiting toxicities (DLT s) and maximum
tolerated dose (MTD) of the first in class NEDD 8‐activating enzyme (NAE) inhibitor …